News

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will share the following poster presentations: Bioequivalence of ZUNVEYL,.

07/08/2025

What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock

Alpha Cognition Inc. (ACOG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

07/04/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Alpha Cognition Inc. Common Stock (ACOG) a buy, sell, or hold?

Alpha Cognition Inc. Common Stock (ACOG) can sell. Click on Rating Page for detail.

What is Alpha Cognition Inc. Common Stock's stock price?

The price of Alpha Cognition Inc. Common Stock (ACOG) is 10.225 and it was updated on 2025-07-18 09:00:37.

Is Alpha Cognition Inc. Common Stock (ACOG) overvalued or undervalued?

Currently Alpha Cognition Inc. Common Stock (ACOG) is in undervalued.

News

From:

To:

News
Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The data provides additional evidence of benefits of ALPHA-1062, in the treatment of mTBI resulting from repetitive blast. Tue, Jul. 01, 2025
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year? Here is how Alpha Cognition Inc. (ACOG) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year. Tue, Jul. 01, 2025
Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross? Alpha Cognition Inc. (ACOG) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACOG's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross. Mon, Jun. 16, 2025
Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity Zunveyl nearly eliminates the onerous GI and sleep disturbance side effects of gold-standard AChEI drugs used to treat Alzheimer's. With failure of anti-amyloid antibodies and no clear disease-modifying therapies in late-stage development (yet), the $5.5 billion Alzheimer's market is severely underserved and dissatisfied. Lean, experienced commercial team launched Zunveyl in March into the long-term care (LTC) market vertical, which accounts for 32% of Alzheimer's scripts. Mon, May. 19, 2025
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025 Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition began 2025 by launching ZUNVEYL(R) (benzgalantamine) to the U.S. long-term care (LTC) market on March 17, 2025, delivering on its commercialization timeline and budget. Mon, May. 19, 2025

Transcripts

Transcipts Data
Alpha Cognition Inc. Common Stock (ACOG) on Q1 2025 Results - Earnings Call Transcript SA Transcripts Thu, May. 15, 2025
Alpha Cognition Inc. Common Stock (ACOG) on Q4 2024 Results - Earnings Call Transcript SA Transcripts Mon, Mar. 31, 2025

SEC Filings

SEC Filings
Alpha Cognition Inc. Common Stock (ACOG) - 424B3 SEC Filings 07/17/2025
Alpha Cognition Inc. Common Stock (ACOG) - EFFECT SEC Filings 07/09/2025
Alpha Cognition Inc. Common Stock (ACOG) - S-3 SEC Filings 07/01/2025
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 06/23/2025
Alpha Cognition Inc. Common Stock (ACOG) - 10-Q - Quarterly Report SEC Filings 05/15/2025
Alpha Cognition Inc. Common Stock (ACOG) - DEFA14A SEC Filings 05/06/2025
Alpha Cognition Inc. Common Stock (ACOG) - DEF 14A SEC Filings 04/30/2025
Alpha Cognition Inc. Common Stock (ACOG) - 4 SEC Filings 04/29/2025
Alpha Cognition Inc. Common Stock (ACOG) - SCHEDULE 13G SEC Filings 04/16/2025
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 04/10/2025
Alpha Cognition Inc. Common Stock (ACOG) - 4 SEC Filings 04/09/2025
Alpha Cognition Inc. Common Stock (ACOG) - 3 SEC Filings 04/09/2025
Alpha Cognition Inc. Common Stock (ACOG) - 10-K - Current report SEC Filings 03/31/2025
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 02/27/2025
Alpha Cognition Inc. Common Stock (ACOG) - 4 SEC Filings 02/27/2025
Alpha Cognition Inc. Common Stock (ACOG) - SCHEDULE 13G SEC Filings 02/14/2025
Alpha Cognition Inc. Common Stock (ACOG) - SCHEDULE 13G/A SEC Filings 02/13/2025
Alpha Cognition Inc. Common Stock (ACOG) - SCHEDULE 13G SEC Filings 02/13/2025
Alpha Cognition Inc. Common Stock (ACOG) - SCHEDULE 13G SEC Filings 01/31/2025
Alpha Cognition Inc. Common Stock (ACOG) - 424B3 SEC Filings 01/15/2025
Alpha Cognition Inc. Common Stock (ACOG) - EFFECT SEC Filings 01/14/2025
Alpha Cognition Inc. Common Stock (ACOG) - EFFECT SEC Filings 01/14/2025
Alpha Cognition Inc. Common Stock (ACOG) - S-1/A SEC Filings 01/10/2025
Alpha Cognition Inc. Common Stock (ACOG) - POS AM SEC Filings 01/10/2025
Alpha Cognition Inc. Common Stock (ACOG) - CORRESP SEC Filings 01/10/2025
Alpha Cognition Inc. Common Stock (ACOG) - UPLOAD SEC Filings 01/03/2025
Alpha Cognition Inc. Common Stock (ACOG) - S-8 POS SEC Filings 12/31/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1 SEC Filings 12/31/2024
Alpha Cognition Inc. Common Stock (ACOG) - POS AM SEC Filings 12/31/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 12/20/2024
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 11/18/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 11/18/2024
Alpha Cognition Inc. Common Stock (ACOG) - SC 13D/A SEC Filings 11/15/2024
Alpha Cognition Inc. Common Stock (ACOG) - SC 13D SEC Filings 11/15/2024
Alpha Cognition Inc. Common Stock (ACOG) - 4 SEC Filings 11/15/2024
Alpha Cognition Inc. Common Stock (ACOG) - 10-Q - Quarterly Report SEC Filings 11/14/2024
Alpha Cognition Inc. Common Stock (ACOG) - 424B4 SEC Filings 11/13/2024
Alpha Cognition Inc. Common Stock (ACOG) - 3 SEC Filings 11/13/2024
Alpha Cognition Inc. Common Stock (ACOG) - EFFECT SEC Filings 11/12/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1MEF SEC Filings 11/12/2024
Alpha Cognition Inc. Common Stock (ACOG) - POS EX SEC Filings 11/12/2024
Alpha Cognition Inc. Common Stock (ACOG) - CERT SEC Filings 11/12/2024
Alpha Cognition Inc. Common Stock (ACOG) - 3 SEC Filings 11/12/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-A12B SEC Filings 11/08/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1/A SEC Filings 11/06/2024
Alpha Cognition Inc. Common Stock (ACOG) - CORRESP SEC Filings 11/06/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 11/05/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1/A SEC Filings 10/25/2024
Alpha Cognition Inc. Common Stock (ACOG) - CORRESP SEC Filings 10/25/2024
Alpha Cognition Inc. Common Stock (ACOG) - 424B3 SEC Filings 10/25/2024
Alpha Cognition Inc. Common Stock (ACOG) - EFFECT SEC Filings 10/24/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 10/24/2024
Alpha Cognition Inc. Common Stock (ACOG) - UPLOAD SEC Filings 10/23/2024
Alpha Cognition Inc. Common Stock (ACOG) - UPLOAD SEC Filings 10/21/2024
Alpha Cognition Inc. Common Stock (ACOG) - CORRESP SEC Filings 10/21/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-8 SEC Filings 10/16/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1/A SEC Filings 10/16/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1 SEC Filings 10/16/2024
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 10/09/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 10/09/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 10/03/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K/A - Current report SEC Filings 09/26/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 09/25/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 08/28/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 08/27/2024
Alpha Cognition Inc. Common Stock (ACOG) - 424B3 SEC Filings 08/15/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 08/13/2024
Alpha Cognition Inc. Common Stock (ACOG) - 10-Q - Quarterly Report SEC Filings 08/12/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 08/09/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1/A SEC Filings 07/30/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 07/29/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1 SEC Filings 06/14/2024
Alpha Cognition Inc. Common Stock (ACOG) - 8-K - Current report SEC Filings 06/14/2024
Alpha Cognition Inc. Common Stock (ACOG) - EFFECT SEC Filings 06/10/2024
Alpha Cognition Inc. Common Stock (ACOG) - 424B3 SEC Filings 06/10/2024
Alpha Cognition Inc. Common Stock (ACOG) - CORRESP SEC Filings 06/06/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1/A SEC Filings 06/04/2024
Alpha Cognition Inc. Common Stock (ACOG) - DRS SEC Filings 06/04/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1/A SEC Filings 05/22/2024
Alpha Cognition Inc. Common Stock (ACOG) - CORRESP SEC Filings 05/22/2024
Alpha Cognition Inc. Common Stock (ACOG) - UPLOAD SEC Filings 05/21/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1/A SEC Filings 05/10/2024
Alpha Cognition Inc. Common Stock (ACOG) - CORRESP SEC Filings 05/10/2024
Alpha Cognition Inc. Common Stock (ACOG) - UPLOAD SEC Filings 05/08/2024
Alpha Cognition Inc. Common Stock (ACOG) - S-1 SEC Filings 04/30/2024
Alpha Cognition Inc. Common Stock (ACOG) - DRSLTR SEC Filings 04/23/2024
Alpha Cognition Inc. Common Stock (ACOG) - DRS/A SEC Filings 04/23/2024
Alpha Cognition Inc. Common Stock (ACOG) - UPLOAD SEC Filings 04/17/2024
Alpha Cognition Inc. Common Stock (ACOG) - DRS/A SEC Filings 03/21/2024
Alpha Cognition Inc. Common Stock (ACOG) - DRS SEC Filings 02/09/2024
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 01/31/2024
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 01/05/2024
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 11/20/2023
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 10/19/2023
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 09/12/2023
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 03/28/2023
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 02/28/2023
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 10/18/2021
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 12/28/2020
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 05/01/2020
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 10/09/2019
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 07/20/2018
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 12/19/2017
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 04/26/2016
Alpha Cognition Inc. Common Stock (ACOG) - D SEC Filings 10/16/2015

Press Releases

StockPrice Release
Alpha cognition to present zunveyl® (benzgalantamine) study data at alzheimer's association international conference 07/08/2025
Alpha cognition announces positive pre-clinical data for alpha-1062 use in a military relevant model of repetitive mild traumatic brain injury 07/01/2025
Stonegate capital partners updates coverage on alpha cognition inc. (acog) q1 2025 05/19/2025
Alpha cognition inc. reports first quarter 2025 financial results and operating overview 05/15/2025
Alpha cognition, inc. announces participation in the d. boral capital inaugural global conference 04/30/2025
Alpha cognition to present zunveyl® (benzgalantamine) clinical data at 2025 alzheimer's association international conference 04/28/2025
Alpha cognition strengthens its leadership team with appointment of robert wills to board of directors and announces departure of existing director john havens 04/10/2025
Stonegate capital partners updates coverage on alpha cognition inc. (acog) q4 2024 04/01/2025
Alpha cognition inc. reports fourth quarter and full year 2024 financial results and operating overview 03/31/2025
Alpha cognition to report fourth quarter and full year 2024 financial results and operating overview 03/19/2025
Alpha cognition announces the commercial launch of zunveyl (benzgalantamine) for the treatment of mild to moderate alzheimer's disease 03/18/2025
Alpha cognition secures additional u.s. patent for zunveyl (benzgalantamine) in the treatment of mild to moderate alzheimer's disease 02/12/2025
Stonegate capital partners initiates coverage on alpha cognition inc. (acog) 01/30/2025
Alpha cognition announces a $44 million exclusive licensing agreement for the development and commercialization of zunveyl (benzgalantamine), an fda-approved treatment for mild-to-moderate alzheimer's disease, in china 01/08/2025
Alpha cognition to present q1 2025 zunveyl (benzgalantamine) launch strategy targeting the $2 billion u.s. alzheimer's long-term care market during investor update call 01/06/2025
Alpha cognition announces partial exercise of over-allotment option 12/16/2024
Cse bulletin: delist - alpha cognition inc. (acog) 12/16/2024
Alpha cognition announces voluntary delisting from cse 12/12/2024
Alpha cognition announces positive interim pre-clinical data for alpha-1062 use in a military relevant model of repetitive mild traumatic brain injury 12/11/2024
Alpha cognition announces financial results for the second quarter and six months ended june 2024 and provides corporate update 11/15/2024
Alpha cognition announces financial results for the second quarter and six months ended june 2024 and provides corporate update 08/12/2024

More Headlines

News
Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript Alpha Cognition Inc. (NASDAQ:ACOG ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Henry Du - Interim CFO Michael McFadden - CEO Lauren D'Angelo - COO Conference Call Participants Ram Selvaraju - H.C. Wainwright Michael Freeman - Raymond James Dave Storms - Stonegate Operator Greetings and welcome to the Alpha Cognition earnings call. 05/15/2025
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.75 per share a year ago. 05/15/2025
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”) today announced its financial results for the first quarter ended March 31, 2025. “We closed the quarter on a strong note, launching ZUNVEYL® to the long-term care market,” said Michael McFadden, Chief Executive Officer. “We feel that the company is operating at a high level and are on schedule and within budget on all of our launch plans. Early market feedback on ZUNVEYL util. 05/15/2025
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference Grapevine, Texas--(Newsfile Corp. - April 30, 2025) - Alpha Cognition, Inc. (NASDAQ: ACOG), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City. 04/30/2025
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (the “Company” or “Alpha Cognition”) today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the “AAIC”), taking place July 27–31, 2025 in Toronto, Canada. The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially laun. 04/28/2025
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens VANCOUVER & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate str. 04/10/2025
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 Dallas, Texas--(Newsfile Corp. - April 1, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition had a strong 2024 after raising $52.8M and uplisting to NASDAQ, significantly enhancing its capital base and market visibility. 04/01/2025
Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript Alpha Cognition Inc. (NASDAQ:ACOG ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Henry Du - Interim Chief Financial Officer Michael McFadden - Chief Executive Officer Lauren D'Angelo - Chief Operating Officer Conference Call Participants Michael Freeman - Raymond James Dave Storms - Stonegate Operator Greetings, and welcome to the Alpha Cognition Earnings Call. At this time, all participants are in a listen-only mode. 03/31/2025
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”) today announced its financial results for the fourth quarter and full year ended December 31, 2024. “We closed 2024 on a strong note, securing capital to support the ZUNVEYL commercial launch and assembling an experienced leadership team,” said Michael McFadden, Chief Executive Officer. “In early 2025, we completed the manufacturing of the initial commercial supply of ZUNVEYL. 03/31/2025
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the. 03/19/2025
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer's disease. This milestone marks a major step forward in the company's mission to provide innovative and accessible solutions for patients and caregivers — and to deliver new hope to the millions impacted by. 03/18/2025
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease VANCOUVER--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent titled “Coated Tablets for pH-Dependent Release of Benzgalantamine.” This newly issued patent strengthens Alpha Cognition's intellectual property portfolio by covering the composition of. 02/12/2025
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) Dallas, Texas--(Newsfile Corp. - January 30, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners initiates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition Inc. reported significant progress in 2024 so far, marked by key financial and corporate milestones. 01/30/2025
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS) (867.HK), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the People's Republic of China, today announced an exclusive licensing agreement for the. 01/08/2025
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced it will host an investor update call on Tuesday, January 28th, 2025 at 4pm EST to present its commercial launch strategy for ZUNVEYL (benzgalantamine), an FDA-approved treatment for mild-to-moderate Alzheimer's disease (AD). The call will focus on the company's plans t. 01/06/2025
Alpha Cognition Announces Partial Exercise of Over-allotment Option VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced that the underwriters of its underwritten U.S. public offering (the “Offering”) have partially exercised their over-allotment option to purchase an additional 488,506 common shares at the public offering price of US$5.75 per share for an a. 12/16/2024
CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG) Toronto, Ontario--(Newsfile Corp. - Le 16 décembre/December 2024) - The common shares of Alpha Cognition Inc. will be delisted from the CSE at market close December 17, 2024. Alpha Cognition will continue to trade on the Nasdaq. 12/16/2024
Alpha Cognition Announces Voluntary Delisting from CSE VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company's listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange. The shares will be delisted from the Canadian Securities Exchange at the close of trading on December 17, 2024. The Company's common shares will continue to trade on the Nasdaq under the symb. 12/12/2024
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced interim preclinical data that supports the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The interim data provides evidence of benefit for ALPHA-1062, in the treatment of mTBI resulting f. 12/11/2024
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended September 30, 2024, and provided a corporate update. “The FDA approval of ZUNVEYL represents an important breakthrough for patients with Alzheimer's disease. Alpha Cognition is focused. 11/15/2024
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended June 30, 2024, and provided a corporate update. “The FDA approval of ZUNVEYL represents an important breakthrough for patients with Alzheimer's disease. This approval marks a pivotal mom. 08/12/2024

Unlock

ACOG Ratings Summary

ACOG Quant Ranking

Is Alpha Cognition Inc. Common Stock (ACOG) a buy, sell, or hold?

What is Alpha Cognition Inc. Common Stock's stock price?

Is Alpha Cognition Inc. Common Stock (ACOG) overvalued or undervalued?

Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript

Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease